SQZ News and Press, SQZ Biotechnologies Company From 09/27/21

SQZ Biotechnologies (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced that management will be presenting at the Cantor Global Healthcare Conference on September 29. Armon Sharei, Ph.D., Chief Executive Officer, wil...

IND filing for Celiac Disease Anticipated in Third Quarter 2022 Clinical Translation Supported by Existing Red Blood Cell-Based Manufacturing Capabilities and Preclinical Models Demonstrating Treg Mediated Tolerance SQZ Biotechnologies (NYSE: SQZ), focused on unlocki...

SQZ Biotechnologies (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced that management will be presenting at Citi’s 16 th Annual Virtual Biopharma Conference on September 10, and at the H. C. Wainwright...

MaxCyte has become the go-to partner for biotech companies using non-viral cell engineering, aided by its proprietary patented flow electroporation technology. The company has a scalable (licenses and SPLs) business model with recurring revenues. Milestone and royalty payments (at 100...

SQZ Biotechnologies (NYSE:SQZ): Q2 GAAP EPS of -$0.68 misses by $0.10. Revenue of $4.54M (-24.1% Y/Y) misses by $1.25M. Press Release For further details see: SQZ Biotechnologies EPS misses by $0.10, misses on revenue

SQZ Biotechnologies (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today reported second quarter 2021 financial results and recent portfolio updates. “This was an exciting quarter for the company as we reported first-in-...

SQZ Biotechnologies ([[SQZ]] +2.6%) has appointed Bernard Coulie and Patrick Vink to its board of directors.Coulie is currently president and CEO of Pliant Therapeutics.Vink is currently a board chair or director in biotechnology companies in Denmark, Switzerland, UK, and ...

Bernard Coulie, M.D., Ph.D. and Patrick Vink, M.D. Join Board of Directors SQZ Biotechnologies (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced the appointments of Bernard Coulie, M.D., Ph.D., and Patr...

Results Further Establish Company’s Broad Cell Engineering Capabilities and Potential to Direct Cell Fate for Multiple Therapeutic Applications Findings Presented at 2021 International Society for Stem Cell Research Annual Meeting SQZ Biotechnologies Company (...

Engineered TACs Prevented Hyperglycemia in Type 1 Diabetes Models by Deletion of Target T Cells and Increase of Regulatory T Cells that Exerted Potent Bystander Suppression Data Presented at Federation of Clinical Immunology Societies SQZ Biotechnologies Company ...